177 related articles for article (PubMed ID: 23840510)
1. Tamoxifen and ovarian function.
Berliere M; Duhoux FP; Dalenc F; Baurain JF; Dellevigne L; Galant C; Van Maanen A; Piette P; Machiels JP
PLoS One; 2013; 8(6):e66616. PubMed ID: 23840510
[TBL] [Abstract][Full Text] [Related]
2. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
3. [Tolerance of Tamoxifen as an adjuvant therapy and long-term follow up of 55 premenopausal breast cancer women, cared for at the Institut de cancérologie de Lorraine, treated with Tamoxifen].
Sebaoun P; Frederic M; Weryha G; Hamdaoui SE; Salleron J; Lesur A
Bull Cancer; 2019 Dec; 106(12S1):S75-S100. PubMed ID: 32008741
[TBL] [Abstract][Full Text] [Related]
4. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.
Yamazaki R; Inokuchi M; Ishikawa S; Ayabe T; Jinno H; Iizuka T; Ono M; Myojo S; Uchida S; Matsuzaki T; Tangoku A; Kita M; Sugie T; Fujiwara H
BMC Cancer; 2020 Jan; 20(1):67. PubMed ID: 31996163
[TBL] [Abstract][Full Text] [Related]
5. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
6. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report.
Kim HJ; Noh WC; Nam SJ; Park BW; Lee ES; Im SA; Jung YS; Yoon JH; Kang SS; Park KH; Lee SJ; Jeong J; Lee MH; Cho SH; Kim SY; Kim HA; Han SH; Han W; Hur MH; Kim S; Ahn SH
Eur J Cancer; 2021 Jul; 151():190-200. PubMed ID: 34010788
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
Guerrero A; Gavilá J; Folkerd E; Ortiz B; Martínez F; García A; Climent MA; Guillem V; Ruíz A
Ann Oncol; 2013 Mar; 24(3):674-9. PubMed ID: 23108951
[TBL] [Abstract][Full Text] [Related]
8. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
[TBL] [Abstract][Full Text] [Related]
9. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
Yasumura T; Oka T; Honjo H; Okada H
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
[TBL] [Abstract][Full Text] [Related]
10. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
[No Abstract] [Full Text] [Related]
13. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
14. Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.
Xue C; Peng R; Cao Y; Wang S; Shi Y; An X; Xu F; Yuan Z
PLoS One; 2016; 11(2):e0148849. PubMed ID: 26866810
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
Klijn JG; Beex LV; Mauriac L; van Zijl JA; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
J Natl Cancer Inst; 2000 Jun; 92(11):903-11. PubMed ID: 10841825
[TBL] [Abstract][Full Text] [Related]
16. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
17. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
Swain SM; Land SR; Ritter MW; Costantino JP; Cecchini RS; Mamounas EP; Wolmark N; Ganz PA
Breast Cancer Res Treat; 2009 Jan; 113(2):315-20. PubMed ID: 18302020
[TBL] [Abstract][Full Text] [Related]
18. Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
Kim H; Han W; Ku SY; Suh CS; Kim SH; Choi YM
J Gynecol Oncol; 2017 Mar; 28(2):e10. PubMed ID: 27894163
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?
Cameron DA; Douglas S; Brown JE; Anderson RA
Breast Cancer Res Treat; 2010 Oct; 123(3):805-14. PubMed ID: 20686833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
